PT  - JOURNAL ARTICLE
AU  - Yorsaeng, Ritthideach
AU  - Vichaiwattana, Preeyaporn
AU  - Klinfueng, Sirapa
AU  - Wongsrisang, Lakkhana
AU  - Sudhinaraset, Natthinee
AU  - Vongpunsawad, Sompong
AU  - Poovorawan, Yong
TI  - Immune response elicited from heterologous SARS-CoV-2 vaccination: Sinovac (CoronaVac) followed by AstraZeneca (Vaxzevria)
AID  - 10.1101/2021.09.01.21262955
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.09.01.21262955
4099  - http://medrxiv.org/content/early/2021/09/03/2021.09.01.21262955.short
4100  - http://medrxiv.org/content/early/2021/09/03/2021.09.01.21262955.full
AB  - Limited COVID-19 vaccines in many countries have delayed mass-immunization. Although individuals fully vaccinated with Vaxzevria (AstraZeneca) have higher antibody levels than those with CoronaVac (Sinovac), heterologous prime-boost with CoronaVac-Vaxzevria yielded comparable antibody levels to two-dose Vaxzevria. Combination use of different available vaccines may be warranted in Thailand, which faces limited vaccine choice and supply.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by The National Research Council of Thailand (NRCT), Health Systems Research Institute, The Center of Excellence in Clinical Virology of Chulalongkorn University, and King Chulalongkorn Memorial Hospital.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Board of Chulalongkorn University (IRB number 192/64)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available and included in this study.